Apr '26: Paper Alert!

Allergic asthma is driven by type 2 immune responses in which Group 2 innate lymphoid cells (ILC2s) play a central role, yet the mechanisms that naturally limit their activity remain incompletely understood. We found that Tim-3, a protein known for regulating T cell responses, also acts as a natural "off switch" for ILC2s — its expression rises when ILC2s become activated, and engaging it dials back their inflammatory activity by suppressing a specific signaling pathway and reducing cellular energy production. In mouse models of allergic airway disease, Tim-3 activation reduced airway inflammation and hyperreactivity, while removing Tim-3 specifically from ILC2s made disease worse. These findings were confirmed in human ILC2s and humanized mice, strengthening their translational relevance. This work establishes Tim-3 as a key inhibitory checkpoint in innate type 2 immunity and highlights it as a promising therapeutic target for allergic asthma and related conditions. 

Click here to read more!